ImmunityBio Investors Urged to Lead Class Action Lawsuit After FDA Warning

ImmunityBio Faces Legal Challenge: Investors Act Promptly

ImmunityBio, Inc. (NASDAQ: IBRX) is currently embroiled in a significant class action lawsuit. This legal action arises from a series of events that have negatively impacted the company's stock price and investor confidence. The lawsuit is initiated by a well-known national shareholder rights firm, Hagens Berman, which seeks to represent investors who bought shares between January 19, 2026, and March 24, 2026.

The backdrop of this lawsuit is a warning from the U.S. Food and Drug Administration (FDA) regarding misleading claims made by ImmunityBio's executive chairman and Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong. During a promotional podcast aired on January 19, Dr. Soon-Shiong asserted that ImmunityBio's flagship product, Anktiva, could treat all cancers, despite it only being FDA-approved for non-muscle invasive bladder cancer (NMIBC). This claim was flagged as misleading by the FDA, which subsequently issued a formal warning letter to ImmunityBio.

The fallout from this controversy dramatically impacted ImmunityBio's stock price, which plummeted by over 21% on March 24, 2026, wiping out nearly $2 billion from the company's market capitalization. Investors who had seen their portfolios affected by this downturn are encouraged to act swiftly to join the class action, as the deadline for leading the charge is set for May 26, 2026.

Background of ImmunityBio and Its Technology

ImmunityBio, Inc. is pioneering the development of next-generation immunotherapies aimed at enhancing the body’s immune system to fight against various cancers and infectious diseases. The biotechnology firm’s product, Anktiva, has garnered attention for its potential applications. However, the recent backlash highlights the fine line between aggressive marketing and regulatory compliance in the pharmaceutical industry.

The FDA's warning letter specifically called out the promotional materials used by ImmunityBio, which suggested that Anktiva could cure and prevent all types of cancers without substantiating evidence to back these claims. The letter emphasized the issue of misleading representations of Anktiva's efficacy and its approved uses, raising serious concerns from a public health perspective.

Legal Implications and Next Steps for Investors

The ongoing investigation led by Hagens Berman aims to determine whether ImmunityBio deliberately misled its investors regarding the effectiveness of Anktiva. Reed Kathrein, the partner leading the case, has encouraged investors who experienced significant losses to come forward with their claims. Additionally, witnesses who might assist in the investigation are urged to reach out to the firm's legal team.

Investors should be aware that they have legal rights and options available to them. Those considering filing a claim or joining the class action lawsuit are advised to submit their losses to ensure their voices are heard in this substantial legal battle.

Hagens Berman has a proven track record, having secured over $2.9 billion in settlements for investors facing corporate misconduct. With this class action, the law firm is striving to hold ImmunityBio accountable if allegations of deceit regarding Anktiva are substantiated.

Conclusion

As the situation unfolds, affected ImmunityBio investors hit by the recent stock dip should take immediate action to protect their financial interests. The class action lawsuit represents a critical opportunity for them to seek justice and potentially recover their losses. As the deadline looms, prompt decisions and actions are advised. For more information or to connect with Hagens Berman, visit their dedicated case page or reach out via their contact channels.

For further updates and to follow the progress of the class action lawsuit, stay tuned for announcements from Hagens Berman, as key developments are likely to impact both the company's future and investor outcomes.